GATA3 and clear cell adenocarcinoma: Based on the results of this study, GATA3 expression was observed in 18% of endocervical, 7% of endometrial, and 10% of ovarian carcinomas, including 7% of serous and 13% of clear cell carcinomas, often with low intensity (H score<50).